Ethical priorities for international collaborative adaptive platform trials for public health emergencies

Datos Bibliográficos

ID21880467
AutoresKatharine Wright (0009-0004-4272-1591, World Health Organization, autor de correspondencia), Joseph Ali (0000-0002-4767-2512, Johns Hopkins University), Alun M Davies (0000-0001-7784-9000, University of Oxford), P Glasziou (0000-0001-7564-073X, Bond University), Nina H Gobat (0000-0002-1558-557X, World Health Organization), Tanja Kuchenmüller (0000-0002-9021-981X, World Health Organization), Katherine Littler (0000-0003-3679-6031, Health Ethics and Governance Unit, WHO, Geneva, GE, Switzerland), Chelsea Modlin (0000-0001-9005-9812, Johns Hopkins University), Lee-Anne Pascoe (0000-0001-9167-5799, Health Ethics and Governance Unit, WHO, Geneva, GE, Switzerland), Andreas Reis (0000-0002-8218-2615, Health Ethics and Governance Unit, WHO, Geneva, GE, Switzerland), Jerome Amir Singh (0000-0002-6275-6853, University of KwaZulu-Natal)
Año2023
Volumen8
Número7
Páginase012930
Fecha de publicación2023-07-01
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaBMJ Global Health (JOURNAL)
Identificadores de la revistaISSN: 2059-7908 • E-ISSN: 2059-7908
EditorialBMJ (PUBLISHER • GB)
DOI10.1136/bmjgh-2023-012930
PMID37524503
OpenAlexW4385412055
IdiomaEN
Referencias citadas7

Rapidly produced evidence on effective medical counter measures is critical for responding to health emergencies caused by (re-)emerging infectious diseases. Adaptive platform trials played a significant role in the global research response to COVID-19 and are likely to be increasingly used in the future, both in emergency and non-emergency contexts. We call attention to a number of ethical considerations that should influence the development and future implementation of large-scale multicountry adaptive platform studies

Engineering ethics · Political science · Public health · Public relations · Biomedical Ethics and Regulation · Engineering · Ethics in Clinical Research · Medicine · Nursing · Public Administration